Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1806 | Pictilisib | pan PI3K | PI3K/mTOR | 5.8714 | 0.1936 | 0.1178 | 0.0220 | 1.3031 | 13.6419 | 0.96395 |
HCC1395 | Saracatinib | SRC | MAPK/nRTK | 3.7809 | 0.1199 | 0.1181 | 0.0202 | 0.9275 | 10.2114 | 0.93832 |
HCC70 | Alpelisib | PI3Ka | PI3K/mTOR | 4.4987 | 0.0981 | 0.1182 | 0.0196 | 1.0448 | 12.8744 | 0.95143 |
HCC38 | Pictilisib | pan PI3K | PI3K/mTOR | 6.5531 | 0.3569 | 0.1182 | 0.0066 | 0.7184 | 30.2402 | 0.97968 |
HCC1428 | ABT-737 | Bcl2/XL | Misc | 4.0616 | 0.2431 | 0.1194 | 0.0716 | 1.0222 | 5.0858 | 0.98165 |
HCC1806 | Bleomycin | Radiation | Misc | 8.9432 | 0.4813 | 0.1206 | 0.0253 | 0.8891 | 1.9034 | 0.96208 |
HCC1500 | Cisplatin | Chemo | Chemotherapy | 3.4531 | 0.2076 | 0.1210 | -0.0094 | 5.0000 | 3.1071 | 0.92762 |
SUM149PT | Pictilisib | pan PI3K | PI3K/mTOR | 5.8499 | 0.3333 | 0.1214 | 0.0038 | 0.7167 | 27.0916 | 0.9899 |
HCC38 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.7055 | 0.1225 | 0.0092 | 1.1410 | 0.22841 | 0.9721 |
CAL-85-1 | Cabozantinib | VEGFR2/MET | RTK | 5.3386 | 0.1728 | 0.1229 | 0.0278 | 1.1624 | 13.7367 | 0.96943 |
SUM1315MO2 | Ipatasertib | AKT | PI3K/mTOR | 36.6304 | 0.6070 | 0.1242 | 0.0099 | 0.3263 | 999.2697 | 0.9146 |
T47D | Cediranib | VEGFR/cKIT | RTK | 4.1027 | -0.6403 | 0.1246 | 0.0754 | 2.9281 | 5.9706 | 0.99504 |
MCF 10A | Saracatinib | SRC | MAPK/nRTK | 4.8259 | 0.1485 | 0.1247 | 0.0066 | 1.0801 | 13.3454 | 0.99696 |
SUM149PT | Ipatasertib | AKT | PI3K/mTOR | 4.6451 | 0.2929 | 0.1261 | 0.0067 | 0.9023 | 6.7816 | 0.99801 |
BT-549 | Abemaciclib | CDK4/6 | Cell cycle | 3.9707 | 0.0333 | 0.1267 | 0.0188 | 1.2825 | 7.5655 | 0.99654 |
T47D | PF-4708671 | p70S6K | PI3K/mTOR | 3.7629 | 0.3659 | 0.1275 | 0.0024 | 1.0704 | 1.8083 | 0.98136 |
BT-549 | Trametinib | MEK | MAPK/nRTK | 5.2409 | 0.5983 | 0.1292 | 0.0152 | 0.5005 | 0.36186 | 0.97942 |
CAL-120 | Ipatasertib | AKT | PI3K/mTOR | 58.682 | 0.5993 | 0.1297 | -0.0033 | 0.4437 | 5.6283 | 0.9635 |
MDA-MB-157 | PF-4708671 | p70S6K | PI3K/mTOR | 3.8142 | 0.1104 | 0.1302 | 0.0024 | 0.9701 | 10.2569 | 0.97748 |
HCC1500 | Cediranib | VEGFR/cKIT | RTK | 3.8594 | -0.8084 | 0.1304 | 0.0735 | 3.4916 | 5.2864 | 0.99235 |
MDA-MB-231 | Bleomycin | Radiation | Misc | 6.333 | 0.4365 | 0.1320 | 0.0030 | 1.0810 | 2.968 | 0.97684 |
T47D | AZD7762 | CHK1/2 | Cell cycle | 2.3432 | -0.0573 | 0.1322 | 0.0195 | 2.6709 | 2.4809 | 0.98871 |
PDX1328 | Ipatasertib | AKT | PI3K/mTOR | 4.7978 | 0.3012 | 0.1323 | 0.0153 | 0.6377 | 26.7942 | 0.95509 |
MDA-MB-436 | Pictilisib | pan PI3K | PI3K/mTOR | 5.2741 | 0.2850 | 0.1328 | 0.0124 | 0.7767 | 21.6999 | 0.98441 |
Hs 578T | Cabozantinib | VEGFR2/MET | RTK | 6.3728 | 0.2155 | 0.1335 | 0.0452 | 1.3885 | 14.0588 | 0.89112 |